Study type: Human research · Status: Verified against declared source

Cerebrolysin Concentrate: Therapeutic Potential for Severe Oral Apraxia After Stroke: A Case Report

2024

Study scale: Not reported

Abstract only: Open source record

Product or molecular entity relationships

Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Cerebrolysin concentrate is a medication whose main active ingredient is brain-derived neurotrophic factor.

Limitations and uncertainty

Cerebrolysin concentrate is a medication whose main active ingredient is BDNF, which belongs to the category of neuropeptide preparations [57].

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.